WO2011074484A1 - PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES - Google Patents

PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES Download PDF

Info

Publication number
WO2011074484A1
WO2011074484A1 PCT/JP2010/072182 JP2010072182W WO2011074484A1 WO 2011074484 A1 WO2011074484 A1 WO 2011074484A1 JP 2010072182 W JP2010072182 W JP 2010072182W WO 2011074484 A1 WO2011074484 A1 WO 2011074484A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
molar equivalents
process according
acids
alkyl
Prior art date
Application number
PCT/JP2010/072182
Other languages
French (fr)
Inventor
David Voigtlander
Michael Sander
Michael Harre
Original Assignee
Libramedicina, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10163406A external-priority patent/EP2388257A1/en
Priority to BR112012014490-1A priority Critical patent/BR112012014490B1/en
Priority to CA2784399A priority patent/CA2784399C/en
Priority to SG2012044368A priority patent/SG181745A1/en
Priority to AU2010331367A priority patent/AU2010331367B2/en
Priority to JP2012527135A priority patent/JP5616968B2/en
Application filed by Libramedicina, Inc. filed Critical Libramedicina, Inc.
Priority to NZ601222A priority patent/NZ601222A/en
Priority to MX2012006872A priority patent/MX2012006872A/en
Priority to RU2012130422/04A priority patent/RU2559364C2/en
Priority to CN201080057198.7A priority patent/CN102656154B/en
Priority to KR1020127018741A priority patent/KR101814549B1/en
Priority to EP10801279.0A priority patent/EP2513081B1/en
Publication of WO2011074484A1 publication Critical patent/WO2011074484A1/en
Priority to IL220357A priority patent/IL220357A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Definitions

  • the present invention relates to a process for preparing 1 -O-acyl-2-deoxy-2- fluoro-4-thio- -D-arabinofuranoses and intermediates thereof.
  • the invention relates in particular to a novel process for preparing compounds of formula I
  • R 3 and R 4 represent alkyl, silyl or acyl, and R 5 represents acyl.
  • the starting material in Scheme 1 is the commercially available 1 ,2:5,6-di-0- isopropylidene-a-D-allofuranose (A1 ) which for its part can be obtained in four steps from D-glucose [D.C. Baker et al, Carbohydr. Res. 1972, 24, 192-197].
  • compound II can be obtained in a total of 14 chemical steps starting with 1 ,2:5,6-di-0- isopropylidene-a-D-allofuranose or 18 chemical steps starting with D-glucose.
  • compound II is obtained as an anomeric mixture consisting of Ma and ⁇ .
  • the literature does not make any statements about the ratio Ma / 11 (3 [Y.
  • the process comprises at least five preparative chromatographic separations (prep- HPLC).
  • Compound B1 can be prepared in 6 steps from L-xylose (which does not occur in nature) [J.K. Watts et al, J. Org. Chem. 2006, 71, 921 -925].
  • compound II can be prepared in a total of 13 chemical steps from L-lyxose.
  • the process according to the invention uses exclusively reagents which are readily available even in kg amounts.
  • Steps IX, XI and XII are likewise not isolated and directly used as crude materials for the subsequent step.
  • the oxidation of the sulphide XII can be carried out in a targeted manner at room temperature using OXONE (potassium monopersulphate triple salt, 2 KHS0 5 * KHS0 4 * K 2 SO 4 ), overoxidation can be excluded without any problems by using equimolar amounts (cf. Scheme 2, reaction yielding B7).
  • the Pummerer rearrangement (XIII ⁇ I) is carried out in the presence of catalytic amounts of potassium bisulphate.
  • this catalyst it is possible to achieve high yields (> 80%) and at the same time very little side-product formation ( ⁇ 5%) at low reaction temperatures ( ⁇ 90°C) [cf. Scheme 2, reaction yielding II].
  • the crude product I obtained comprises so few impurities and also only very small proportions of the a-anomer that a simple crystallization is sufficient for purification.
  • the process according to the invention does make use of general chemical transformations, known to the person skilled in the art, for constructing a thiofuranose via formation of a diol, its activation via a bissulphonate and cyclization with sodium sulphide; for protective group techniques and for oxidizing a sulphide with OXONE.
  • general chemical transformations known to the person skilled in the art, for constructing a thiofuranose via formation of a diol, its activation via a bissulphonate and cyclization with sodium sulphide; for protective group techniques and for oxidizing a sulphide with OXONE.
  • a particular aspect of the present invention is the targeted and highly efficient construction of the individual stereocentres of the thiofuranoses.
  • a further aspect of the present invention is the stereospecific introduction of the fluorine atom at the C3 atom of compound X via stereoselective opening of the cyclic sulphate IX.
  • Ri represents -C(0)-d-C 6 -alkyl or -C(0)-aryl
  • R 2 represents CrC 6 -alkyl, Ci-C 4 -perfluoroalkyl or aryl,
  • R 6 represents C C 6 -alkyl or arylmethylene
  • R 7 and R 8 independently of one another represent hydrogen, Ci-C 6 -alkyl, Ci-C 4 - perfluoroalkyl or aryl; is reduced in the presence of 0.5-10 molar equivalents of hydride donors of the formula A(AIH 4 ) or A(BH 4 ), in which A represents an alkali metal, to give the diol of formula V:
  • the reaction step is preferably carried out at a temperature between 0°C and 30°C.
  • the diol V is reacted with at least 2 molar equivalents of sulphonyl chloride R 9 -S0 2 CI or sulphonic anhydride R9-SO2-O-SO2-R9, in which R 9 represents CrC 6 -alkyl, C 1 -C 4 -perfluoroalkyl or aryl, preferably 2-5 molar equivalents of methanesulphonyl chloride, in the presence of at least 2 molar equivalents of a tertiary amine (for example trimethylamine, triethylamine, diisopropylethylamine) or a pyridine (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines), preferably 2-5 molar equivalents of triethylamine, to give a compound of formula VI:
  • the reaction step is preferably carried out at a temperature between 0°C and 30°C.
  • the bissulphonate VI is reacted with at least 1 molar equivalent of sodium sulphide (Na 2 S) in a polar aprotic solvent, such as, for example, DMF, NMP, DMA, DMSO, DMEU, preferably NMP (N-methylpyrrolidone), at a temperature of more than 50°C, preferably at temperatures between 50 and 100°C, to give the thiofuranose of formula VII:
  • step four the thiofuranose of formula VII is converted in a solvent mixture of water and an organic solvent selected from the group of the ethers (for example diethyl ether, THF, dioxane, MTBE), alcohols (for example methanol, ethanol, isopropanol), carboxylic acids (for example acetic acid), aromatic hydrocarbons (for example benzene, toluene), preferably in a mixture of tetrahydrofuran (THF) and water, with 0.01 -5 molar equivalents of an acid selected from the group of the mineral acids (for example HCI, H 2 S0 4 , H3PO 4 ), alkanesulphonic acids (for example methanesulphonic acid),
  • an organic solvent selected from the group of the ethers (for example diethyl ether, THF, dioxane, MTBE), alcohols (for example methanol, ethanol, isopropanol), carboxylic acids (for example acetic acid), aromatic
  • arylsulphonic acids for example benzenesulphonic acid, toluenesulphonic acid
  • perfluorosulphonic acids for example trifluoromethanesulphonic acid
  • nonafluorobutanesulphonic acid or perfluoroalkanecarboxylic acids (for example trifluoroacetic acid), preferably 0.01 -5 molar equivalents of H 2 S0 4 , into the diol of formula VIII:
  • the reaction step is preferably carried out at a temperature between 20°C and 100°C.
  • the diol VIII is isolated by crystallization from a solvent mixture of an alkane or mixtures thereof - preferably heptane - and a carboxylic ester - preferably isopropyl acetate or ethyl acetate.
  • step five the diol of general formula VIII is reacted in the presence of at least 0.2 molar equivalents of a base of the formula AH, A 2 CO3 or A(OtBu), in which A represents an alkali metal; preferably in the presence of 0.2-3 molar equivalents of sodium hydride, with 1 -2 molar equivalents of a diol-activating reagent of the formula X1-SO2-X2, in which and X 2 independently of one another represent CI or imidazoyl, preferably with 1 -2 molar equivalents of sulphonyldiimidazole, to give the cyclic sulphate ester of formula IX:
  • the reaction step is preferably carried out at a temperature between -5°C and 20°C.
  • step six the cyclic sulphate ester of formula IX is initially reacted with 1 -
  • R11 represents CrC 6 -alkyl, preferably with 1 -3 molar equivalents of tetrabutylammonium fluoride, at a temperature between 0°C and 30°C, and the reaction mixture obtained in this manner is reacted with an acid selected from the group of the mineral acids (for example HCI, H 2 S0 4 ), alkylsulphonic acids (for example methanesulphonic acid), arylsulphonic acids (for example benzenesulphonic acid, toluenesulphonic acid), perfluorosulphonic acids (for example trifluoromethanesulphonic acid,
  • mineral acids for example HCI, H 2 S0 4
  • alkylsulphonic acids for example methanesulphonic acid
  • arylsulphonic acids for example benzenesulphonic acid, toluenesulphonic acid
  • perfluorosulphonic acids for example trifluoromethanesulphonic acid
  • nonafluorobutanesulphonic acid or perfluoroalkanecarboxylic acids (for example trifluoroacetic acid), preferably with sulphuric acid (H 2 S0 4 ),
  • the second partial step of the reaction is preferably carried out at a temperature between 20°C and 70°C.
  • step seven the ether of the formula X is initially, in partial step a), reacted in the presence of at least 1 molar equivalent of a boron halide BY 3 , in which Y represents F, CI or Br, preferably using 1 -4 molar equivalents of boron trichloride, at a temperature between 0°C and -80°C.
  • a boron halide BY 3 in which Y represents F, CI or Br, preferably using 1 -4 molar equivalents of boron trichloride, at a temperature between 0°C and -80°C.
  • partial step b) the reaction mixture obtained in partial step a) is reacted with a mixture of
  • an alcohol component selected from the group consisting of a CrC 6 -alkanol (for example methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, isobutanol), an arylalkanol (for example benzyl alcohol) and phenols (for example phenol); and
  • a CrC 6 -alkanol for example methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, isobutanol
  • an arylalkanol for example benzyl alcohol
  • phenols for example phenol
  • a base selected from the group of aliphatic tertiary amines (for example trimethylamine, triethylamine, diisopropylethylamine) or from the group of pyridines (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines);
  • group of aliphatic tertiary amines for example trimethylamine, triethylamine, diisopropylethylamine
  • pyridines for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines
  • the process and quenching of the reaction mixture are preferably carried out at temperatures between 0°C and -80°C.
  • step eight the diol of formula XI is reacted in the presence of at least 2 molar equivalents of a base selected from the group of the aliphatic tertiary amines (for example trimethylamine, triethylamine, diisopropylethylamine) or from the group of the pyridines (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines), preferably using 2-10 molar equivalents of pyridine, with at least 2 molar equivalents of an acid chloride R Ci or an acid anhydride R1-O-R1 , in which R represents -C(0)-CrC 6 -alkyl or -C(0)-aryl; preferably using 2-5 molar equivalents of benzoyl chloride, to give the compound of formula XII:
  • a base selected from the group of the aliphatic tertiary amines (for example trimethylamine, triethyl
  • step nine the sulphide of formula XII is oxidized in a solvent mixture of water and a ketone of the formula R 9 -C(0)-R 9 ' in which R 9 and Rg' independently of one another represent CrC6-alkyl, CrC 4 -perfluoroalkyl or aryl, preferably acetone, with 0.5- 1 molar equivalent of an alkali metal persulphate of the formula AHSO 5 , in which A + represents an alkali metal, preferably using 0.5-1 molar equivalent of OXONE (potassium monopersulphate triple salt, 2 KHS0 5 * KHS0 4 * K 2 S0 4 ), at a temperature between 0°C and 50°C to give the sulphoxide of formula XIII:
  • the product XIII is isolated by crystallization from a suitable solvent, preferably from methyl tert-butyl ether.
  • step ten the sulphoxide of formula XIII is reacted with at least 1 molar equivalent of an acid anhydride R2-C(0)-0-C(0)-R 2 , in which R 2 represents d-C 6 - alkyl, CrC 4 -perfluoroalkyl or aryl; preferably using at least 5 molar equivalents of acetic anhydride, in the presence of 0.01 -2 molar equivalents of a protic acid selected from the group of the mineral acids (for example HCI, HBr, H 2 S0 4 , H 3 P0 4 , alkali metal bisulphates, monobasic alkali metal phosphates), alkanesulphonic acids (for example methanesulphonic acid), arylsulphonic acids (for example benzenesulphonic acid, toluenesulphonic acid), perfluorosulphonic acids (for example trifluoromethanesulphonic acid, nonafluorobutanesulphonic acid) or
  • the product I is isolated by crystallization from a suitable solvent, preferably ethanol.
  • the d-C 6 -alkyl groups of the radicals R 1 f R 2 , Re, Ft?, Re, Rg, Rg', Rn , and Ri 3 can, for example, be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl or n-hexyl groups.
  • the arylmethylene groups of the radicals R 6 , R9, and R13 can, for example, be benzyl or 4-methoxybenzyl groups.
  • the aryl groups of the radicals Ri , R 2 , R7, Re, R9, and R 9 ' can, for example, be phenyl or substituted phenyl groups.
  • Ci-C 4 -perfluoroalkyl groups of the radicals R 2 , R 7 , Re, R9, and R 9 ' can, for example, be trifluoromethyl, pentafluoroethyl or nonafluorobutyl groups.
  • the alkali metals A of the hydride donors of the formulae A(AIH 4 ), A(BH 4 ), of the bases AH, A 2 C0 3 , AOtBu, of the alkali metal persulphates AHSO5 can, for example, be lithium, sodium or potassium.
  • the -C(0)-C C 6 -alkyl groups of the radical Ri can, for example, be acetyl, n- propanoyl, isopropanoyi, n-butanoyl, t-butanoyl, isobutanoyl, n-pentanoyl, or n-hexanoyl groups.
  • the -C(0)-aryl groups of the radical Ri can, for example, be benzoyl or substituted benzoyl groups.
  • the process according to the invention is used for preparing the compound I (according to Scheme 3) in which
  • R1 represents benzoyl
  • R 2 represents methyl
  • R 7 , Re and R 9 represent methyl
  • R 6 represents benzyl
  • the present invention also relates to the intermediates of the preferred embodiment of the process according to the invention (Scheme 4), in particular
  • step C3 50.99 g (215.59 mmol) of sodium sulphide (33% pure) are added to a solution of 86.66 g (179.66 mmol assuming a yield of 100% in step C3) of C3 (crude product) in 550 ml of N-methyl-2-pyrrolidone, and the mixture is heated to an internal temperature of 80°C and stirred at this temperature until the reaction has ended. At an internal temperature of 20°C, water and MTBE are then added, the phases are separated and the aqueous phase is extracted with MTBE. The combined organic phases are finally washed with water. The solution of the crude product is concentrated and freed completely from the solvents. This gives 56.41 g of C4 (1 12%) as a crude product which is used in this form for the subsequent step C5.
  • reaction mixture is then adjusted to pH 1 using sulphuric acid (33% strength) and stirred at 50°C until the reaction is ended.
  • pH is then adjusted to 7-10 using aqueous potassium hydroxide solution, and the precipitate formed is filtered off.
  • the phases are separated and the aqueous phase is extracted with dichloromethane.
  • the combined organic phases are concentrated and the crude product is, after complete removal of the solvent, purified by chromatography. This gives 22.68 g of C7 (45%).
  • the process of the present invention provides an industrially advatageous and excellent preparation of the compounds of the formula I.

Abstract

The present invention relates to a process for preparing 1-O-acyl-2-deoxy-2-fluoro-4-thio-ƒタ-D-arabinofuranoses having formula I and intermediates thereof: wherein R1 represents -C(O)-C1-C6-alkyl or -C(O)-aryl; and R2 represents C1-C6-alkyl, C1-C4-perfluoroalkyl or aryl.

Description

DESCRIPTION
Title of Invention: PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO- -D-ARABINOFURANOSES
Technical Field
[0001] The present invention relates to a process for preparing 1 -O-acyl-2-deoxy-2- fluoro-4-thio- -D-arabinofuranoses and intermediates thereof.
Background Art
[0002] 4'-Thionucleosides are attractive compounds with respect to antiviral and antineoplastic activity. For example, 1-(2-deoxy-2-fluoro-4-thio- -D- arabinofuranosyl)cytosine (4'-thio-FAC) was shown to have excellent antitumour activity in vitro and in vivo [Y. Yoshimura et al; J. Org. Chem. 1997, 62, 3140-3152; S. Miura et al, Cancer Lett. 1998, 129, 103-110; S. Miura et al, Cancer Lett. 1999, 144, 177-182; Y. Yoshimura et al, Bioorg. Med. Chem. 2000, 8, 1545-1558; D.A. Zajchowski et al, Int. J. Cancer 2005, 114, 1002-1009].
[0003] The invention relates in particular to a novel process for preparing compounds of formula I
Figure imgf000002_0001
in which
represents -C(O)-C C6-alkyl or -C(O)-aryl; and
represents CrC6-alkyl, CrCrperfluoroalkyl or aryl.
[0004] The compounds of the general formula I are key intermediates in the preparation of 4'-thionucleosides.
[0005] 1 -(2-Deoxy-2-fluoro-4-thio- -D-arabinofuranosyl)cytosine [4'-thio-FAC]:
Figure imgf000003_0001
[0006] There is a particular interest in the preparation of 1 -(2-deoxy-2-fluoro-4-thio-P- D-arabinofuranosyl)cytosine (4'-thio-FAC) with a view to the compound II:
Figure imgf000003_0002
II where in the text below the a-diastereomer of the anomeric acetate is referred to as Ha and ΙΙβ is used for the β-isomer.
[0007] This compound and its preparation was described for the first time in
WO 97/73993, WO 97/038001 and in the literature associated therewith [Y. Yoshimura et al, J. Org. Chem. 1999, 64, 7912-7920; Y. Yoshimura et al, Nucleosides Nucleotides
1999, 18, 815-820; Y. Yoshimura et al, Nucleic Acids Symposium Series 1998, 39, 1 1 -
12; Y. Yoshimura et al, Tetrahedron Lett. 1999, 40, 1937-1940].
[0008] In this context, a preparation route to compounds of the formula III is described
Figure imgf000004_0001
III
in which
R3 and R4 represent alkyl, silyl or acyl, and R5 represents acyl.
(Scheme 1).
[0009] [Scheme 1]
Figure imgf000005_0001
A10 A11 A12 A 3
BzCI, pyridine
Figure imgf000005_0002
[0010] The starting material in Scheme 1 is the commercially available 1 ,2:5,6-di-0- isopropylidene-a-D-allofuranose (A1 ) which for its part can be obtained in four steps from D-glucose [D.C. Baker et al, Carbohydr. Res. 1972, 24, 192-197]. Thus, compound II can be obtained in a total of 14 chemical steps starting with 1 ,2:5,6-di-0- isopropylidene-a-D-allofuranose or 18 chemical steps starting with D-glucose. Here, compound II is obtained as an anomeric mixture consisting of Ma and Μβ. The literature does not make any statements about the ratio Ma / 11 (3 [Y. Yoshimura et al, J. Org. Chem. 1999, 64, 7912-7920]. Laboratory experiments carried out by the applicant for preparing II analogously to the literature procedure starting with A14 gave ΙΙα/ΙΙβ mixtures of 1 :1 to 3:2.
[001 1] A disadvantage of the process, known from the prior art, for preparing the compound II is the large number of chemical steps required, which makes the practice of the process on an industrial scale considerably more difficult. Furthermore, in particular when the synthesis is carried out on an industrial scale, there are the following difficulties and problems:
• The process comprises at least five preparative chromatographic separations (prep- HPLC).
• The intermediates A6, A7, A9, A12 are unstable.
• Handling of the viscous liquids in stages A2, A3, A4, A8, A9, A1 1 , A12 is difficult.
• The compound A6 dissolves only very slowly in methanol. In the presence of sodium methoxide (NaOMe), a nucleophilic substitution of the mesylate group by a methoxy group in the compound A7 takes place as a side-reaction. Formation of by-product takes place in particular when the reaction is carried out on a relatively large scale.
• After cleavage of the isopropylidene group, trifluoroacetic acid (TFA) has to be
distilled off under reduced pressure since other alternatives for work-up result in a large formation of side-product. On an industrial scale, this is associated with considerable difficulties.
[0012] Owing to the long synthesis sequence and the fact that some of its steps cannot be scaled up, or only with considerable expense, the process shown in Scheme 1 is not suitable for the industrial commercial preparation of the compound II.
[0013] An alternative for preparing the compound II is described in WO 2007/068113 and the literature associated therewith [J.K. Watts et al, J. Org. Chem. 2006, 71, 921 -
925] and is summarized here in Scheme 2.
[0014] [Scheme 2]
Figure imgf000007_0001
Figure imgf000007_0002
[0015] Here, in the last synthesis step, a mixture of the anomeric acetates II in a ratio ΙΙα/ΙΙβ of from 1 :2 to 1 :14 is obtained [see also J.K. Watts et al, J. Org. Chem. 2006, 71, 921 -925]. The by-product B8 is removed by column chromatography.
[0016] Compound B1 can be prepared in 6 steps from L-xylose (which does not occur in nature) [J.K. Watts et al, J. Org. Chem. 2006, 71, 921 -925]. Thus, compound II can be prepared in a total of 13 chemical steps from L-lyxose.
[0017] A particular disadvantage of this synthesis alternative is due to the fact that the starting material L-lyxose is expensive and very little is commercially available for a synthesis on an industrial scale.
[0018] Furthermore, in particular when the synthesis is carried out on an industrial scale, there are the following difficulties and problems:
• On each synthesis stage, complicated protective group transformations and in each case a chromatographic purification have to be carried out.
• The use of liquid ammonia and elemental lithium at very low temperatures (step B2).
• Introduction and removal of a particular silyl protective group which has a high
molar mass and is difficult to obtain commercially (steps B3 and B5).
• Use of DAST as fluorinating agent. In addition to the fact that DAST is difficult to obtain, safety concerns (handling temperature, decomposition of DAST in an exothermal reaction with formation of gas) play an important role in the scale-up of this reaction (step 4).
• The use of ozone at very low temperatures (B7).
• High temperatures (1 10°C) during the Pummerer rearrangement and the formation of about 20% of by-product B8 [J.K. Watts et al, J. Org. Chem. 2006, 71, 921 -925].
[0019] Owing to the difficulties, described here, in the individual steps of the synthesis, which render scale-up difficult or impossible, and owing to the limited availability of the starting material, the process shown in Scheme 2 is likewise not very suitable for the industrial commercial preparation of the compound II.
Summary of Invention
[0020] Against this background, it was the object of the present invention to provide an alternative process allowing the industrial preparation of compounds of formula I.
[0021] According to the invention, this object was achieved by a process which affords compounds of formula I in high yields in 10 chemical steps starting with commercially readily available compounds of formula IV via the key steps "introduction of the fluorine atom via targeted opening of a cyclic sulphate" and "Pummerer rearrangement of a sulphoxide using a special catalyst" (Scheme 3). [0022] [Scheme 3]
Figure imgf000009_0001
XIII I
[0023] Compounds of formula IV, used as starting materials for the process according to the invention, can be synthesized in 4 chemical steps from natural and thus readily available D-ribose. Both D-ribose and compounds of the type IV (for example 5-0- benzyl-2,3-0-isopropylidene-L-lyxono-1 ,4-lactone) are commercially available
(U.S. Patent No. 6,448,415 B1).
[0024] Furthermore, the process according to the invention uses exclusively reagents which are readily available even in kg amounts.
[0025] The intermediates V, VI and VII are isolated only as crude products and in each case employed directly for the next step. Finally, the compound VIII is crystallized in high purity (> 97%). Thus, time- and resource-intensive purifications (for example preparative chromatography) can be dispensed with.
[0026] Steps IX, XI and XII are likewise not isolated and directly used as crude materials for the subsequent step.
[0027] According to the invention, over the entire synthesis sequence, only 3 intermediates (VIII, X and XIII) have to be isolated, and only a single preparative chromatography is required (X). The intermediates VIII, XII and the product I (II) are isolated in high yields and high purities (> 93%) by crystallization.
[0028] The process according to the invention does not require any complicated protective group transformations.
[0029] The oxidation of the sulphide XII can be carried out in a targeted manner at room temperature using OXONE (potassium monopersulphate triple salt, 2 KHS05 * KHS04 * K2SO4), overoxidation can be excluded without any problems by using equimolar amounts (cf. Scheme 2, reaction yielding B7).
[0030] According to the invention, the Pummerer rearrangement (XIII→ I) is carried out in the presence of catalytic amounts of potassium bisulphate. By using this catalyst, it is possible to achieve high yields (> 80%) and at the same time very little side-product formation (< 5%) at low reaction temperatures (< 90°C) [cf. Scheme 2, reaction yielding II]. The crude product I obtained comprises so few impurities and also only very small proportions of the a-anomer that a simple crystallization is sufficient for purification.
[0031] The process according to the invention does make use of general chemical transformations, known to the person skilled in the art, for constructing a thiofuranose via formation of a diol, its activation via a bissulphonate and cyclization with sodium sulphide; for protective group techniques and for oxidizing a sulphide with OXONE. However, a particular aspect of the present invention is the targeted and highly efficient construction of the individual stereocentres of the thiofuranoses.
[0032] A further aspect of the present invention is the stereospecific introduction of the fluorine atom at the C3 atom of compound X via stereoselective opening of the cyclic sulphate IX.
Description of Embodiments
[0033] In the first step of the process according to the invention for preparing a compound of formula I:
Figure imgf000011_0001
in which
Ri represents -C(0)-d-C6-alkyl or -C(0)-aryl; and
R2 represents CrC6-alkyl, Ci-C4-perfluoroalkyl or aryl,
a lyxonolactone of formula IV
Figure imgf000011_0002
in which
R6 represents C C6-alkyl or arylmethylene; and
R7 and R8 independently of one another represent hydrogen, Ci-C6-alkyl, Ci-C4- perfluoroalkyl or aryl; is reduced in the presence of 0.5-10 molar equivalents of hydride donors of the formula A(AIH4) or A(BH4), in which A represents an alkali metal, to give the diol of formula V:
Figure imgf000012_0001
V
[0034] Here, preference is given to using 0.5-1 .5 molar equivalents of lithium aluminium hydride (LiAIH4). The reaction step is preferably carried out at a temperature between 0°C and 30°C.
[0035] In the second step, the diol V is reacted with at least 2 molar equivalents of sulphonyl chloride R9-S02CI or sulphonic anhydride R9-SO2-O-SO2-R9, in which R9 represents CrC6-alkyl, C1-C4-perfluoroalkyl or aryl, preferably 2-5 molar equivalents of methanesulphonyl chloride, in the presence of at least 2 molar equivalents of a tertiary amine (for example trimethylamine, triethylamine, diisopropylethylamine) or a pyridine (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines), preferably 2-5 molar equivalents of triethylamine, to give a compound of formula VI:
Figure imgf000012_0002
VI
[0036] The reaction step is preferably carried out at a temperature between 0°C and 30°C. [0037] In the third step, the bissulphonate VI is reacted with at least 1 molar equivalent of sodium sulphide (Na2S) in a polar aprotic solvent, such as, for example, DMF, NMP, DMA, DMSO, DMEU, preferably NMP (N-methylpyrrolidone), at a temperature of more than 50°C, preferably at temperatures between 50 and 100°C, to give the thiofuranose of formula VII:
Figure imgf000013_0001
VII
[0038] In step four, the thiofuranose of formula VII is converted in a solvent mixture of water and an organic solvent selected from the group of the ethers (for example diethyl ether, THF, dioxane, MTBE), alcohols (for example methanol, ethanol, isopropanol), carboxylic acids (for example acetic acid), aromatic hydrocarbons (for example benzene, toluene), preferably in a mixture of tetrahydrofuran (THF) and water, with 0.01 -5 molar equivalents of an acid selected from the group of the mineral acids (for example HCI, H2S04, H3PO4), alkanesulphonic acids (for example methanesulphonic acid),
arylsulphonic acids (for example benzenesulphonic acid, toluenesulphonic acid), perfluorosulphonic acids (for example trifluoromethanesulphonic acid,
nonafluorobutanesulphonic acid) or perfluoroalkanecarboxylic acids (for example trifluoroacetic acid), preferably 0.01 -5 molar equivalents of H2S04, into the diol of formula VIII:
Figure imgf000014_0001
vm
[0039] The reaction step is preferably carried out at a temperature between 20°C and 100°C.
[0040] The diol VIII is isolated by crystallization from a solvent mixture of an alkane or mixtures thereof - preferably heptane - and a carboxylic ester - preferably isopropyl acetate or ethyl acetate.
[0041] In step five, the diol of general formula VIII is reacted in the presence of at least 0.2 molar equivalents of a base of the formula AH, A2CO3 or A(OtBu), in which A represents an alkali metal; preferably in the presence of 0.2-3 molar equivalents of sodium hydride, with 1 -2 molar equivalents of a diol-activating reagent of the formula X1-SO2-X2, in which and X2 independently of one another represent CI or imidazoyl, preferably with 1 -2 molar equivalents of sulphonyldiimidazole, to give the cyclic sulphate ester of formula IX:
Figure imgf000014_0002
[0042] The reaction step is preferably carried out at a temperature between -5°C and 20°C.
[0043] In step six, the cyclic sulphate ester of formula IX is initially reacted with 1 -
3 molar equivalents of an ammonium fluoride of the formula N(R11)4F, in which
R11 represents CrC6-alkyl, preferably with 1 -3 molar equivalents of tetrabutylammonium fluoride, at a temperature between 0°C and 30°C, and the reaction mixture obtained in this manner is reacted with an acid selected from the group of the mineral acids (for example HCI, H2S04), alkylsulphonic acids (for example methanesulphonic acid), arylsulphonic acids (for example benzenesulphonic acid, toluenesulphonic acid), perfluorosulphonic acids (for example trifluoromethanesulphonic acid,
nonafluorobutanesulphonic acid) or perfluoroalkanecarboxylic acids (for example trifluoroacetic acid), preferably with sulphuric acid (H2S04),
to give the ether of formula X:
Figure imgf000015_0001
X
[0044] The second partial step of the reaction is preferably carried out at a temperature between 20°C and 70°C.
[0045] In step seven, the ether of the formula X is initially, in partial step a), reacted in the presence of at least 1 molar equivalent of a boron halide BY3, in which Y represents F, CI or Br, preferably using 1 -4 molar equivalents of boron trichloride, at a temperature between 0°C and -80°C.
[0046] In partial step b), the reaction mixture obtained in partial step a) is reacted with a mixture of
an alcohol component selected from the group consisting of a CrC6-alkanol (for example methanol, ethanol, n-propanol, isopropanol, n-butanol, t-butanol, isobutanol), an arylalkanol (for example benzyl alcohol) and phenols (for example phenol); and
a base selected from the group of aliphatic tertiary amines (for example trimethylamine, triethylamine, diisopropylethylamine) or from the group of pyridines (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines);
preferably using a mixture of methanol and pyridine, to give the diol of formula XI:
Figure imgf000016_0001
XI
[0047] The process and quenching of the reaction mixture are preferably carried out at temperatures between 0°C and -80°C.
[0048] In step eight, the diol of formula XI is reacted in the presence of at least 2 molar equivalents of a base selected from the group of the aliphatic tertiary amines (for example trimethylamine, triethylamine, diisopropylethylamine) or from the group of the pyridines (for example pyridine, 4-N,N-dimethylaminopyridine, collidine, picolines, lutidines), preferably using 2-10 molar equivalents of pyridine, with at least 2 molar equivalents of an acid chloride R Ci or an acid anhydride R1-O-R1 , in which R represents -C(0)-CrC6-alkyl or -C(0)-aryl; preferably using 2-5 molar equivalents of benzoyl chloride, to give the compound of formula XII:
Figure imgf000016_0002
XII
[0049] In step nine, the sulphide of formula XII is oxidized in a solvent mixture of water and a ketone of the formula R9-C(0)-R9' in which R9 and Rg' independently of one another represent CrC6-alkyl, CrC4-perfluoroalkyl or aryl, preferably acetone, with 0.5- 1 molar equivalent of an alkali metal persulphate of the formula AHSO5, in which A+ represents an alkali metal, preferably using 0.5-1 molar equivalent of OXONE (potassium monopersulphate triple salt, 2 KHS05 * KHS04 * K2S04), at a temperature between 0°C and 50°C to give the sulphoxide of formula XIII:
Figure imgf000017_0001
XIII
[0050] The product XIII is isolated by crystallization from a suitable solvent, preferably from methyl tert-butyl ether.
[0051] In step ten, the sulphoxide of formula XIII is reacted with at least 1 molar equivalent of an acid anhydride R2-C(0)-0-C(0)-R2, in which R2 represents d-C6- alkyl, CrC4-perfluoroalkyl or aryl; preferably using at least 5 molar equivalents of acetic anhydride, in the presence of 0.01 -2 molar equivalents of a protic acid selected from the group of the mineral acids (for example HCI, HBr, H2S04, H3P04, alkali metal bisulphates, monobasic alkali metal phosphates), alkanesulphonic acids (for example methanesulphonic acid), arylsulphonic acids (for example benzenesulphonic acid, toluenesulphonic acid), perfluorosulphonic acids (for example trifluoromethanesulphonic acid, nonafluorobutanesulphonic acid) or perfluoroalkanecarboxylic acids (for example trifluoroacetic acid), or in the presence of 0.01 -2 molar equivalents of a Lewis acid (for example LiCI, MgBr2, Ti(ORi3)4), in which Ri3 represents CrC6-alkyl or arylmethylene; preferably in the presence of 0.01 -2 molar equivalents of potassium bisulphate; at a temperature between 30°C and 100°C to give the compound of formula I:
Figure imgf000018_0001
I
[0052] The product I is isolated by crystallization from a suitable solvent, preferably ethanol.
[0053] Hitherto, the literature does not provide any examples in which potassium bisulphate catalyses the Pummerer rearrangement of a sulphoxide to the corresponding thioacetal and prevents the formation of side-products.
[0054] The d-C6-alkyl groups of the radicals R1 f R2, Re, Ft?, Re, Rg, Rg', Rn , and Ri3 can, for example, be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl or n-hexyl groups.
[0055] The arylmethylene groups of the radicals R6, R9, and R13 can, for example, be benzyl or 4-methoxybenzyl groups.
[0056] The aryl groups of the radicals Ri , R2, R7, Re, R9, and R9' can, for example, be phenyl or substituted phenyl groups.
[0057] The Ci-C4-perfluoroalkyl groups of the radicals R2, R7, Re, R9, and R9' can, for example, be trifluoromethyl, pentafluoroethyl or nonafluorobutyl groups.
[0058] The alkali metals A of the hydride donors of the formulae A(AIH4), A(BH4), of the bases AH, A2C03, AOtBu, of the alkali metal persulphates AHSO5 can, for example, be lithium, sodium or potassium.
[0059] The -C(0)-C C6-alkyl groups of the radical Ri can, for example, be acetyl, n- propanoyl, isopropanoyi, n-butanoyl, t-butanoyl, isobutanoyl, n-pentanoyl, or n-hexanoyl groups.
[0060] The -C(0)-aryl groups of the radical Ri can, for example, be benzoyl or substituted benzoyl groups.
[0061] Preferably, the process according to the invention is used for preparing the compound I (according to Scheme 3) in which
R1 represents benzoyl, and
R2 represents methyl,
i.e. for preparing the compound of formula ΙΙβ.
[0062] According to the present invention, particular preference is given to the process for preparing the compound of formula ΙΙβ (according to Scheme 3) in which
R7, Re and R9 represent methyl, and
R6 represents benzyl.
[0063] Furthermore, the present invention also relates to the intermediates of the preferred embodiment of the process according to the invention (Scheme 4), in particular
1 -0-benzyl-3,4-0-isopropylidene-L-arabinitol (C2);
1 -0-benzyl-3,4-0-isopropylidene-2,5-di-0-methanesulphonyl-L-arabinitol (C3); 1 ,4-anhydro-5-0-benzyl-2,3-0-isopropylidene-4-thio-D-ribitol (C4);
1 ,4-anhydro-5-0-benzyl-2,3-0-sulphonyl-4-thio-D-ribitol (C6);
1 ,4-anhydro-5-0-benzyl-2-deoxy-2-f luoro-4-thio-D-arabinitol (C7) .
[0064] [Scheme 4]
Figure imgf000020_0001
C10 (= B7) IIB
[0065] The compound C1 (5-0-benzyl-2,3-0-isopropylidene-L-lyxono-1 ,4-lactone) is commercially available. Hereinbelow, the procedures for the reactions shown in
Scheme 4 are described.
[0066] Synthesis Procedures
1 -0-Benzyl-3,4-0-isopropylidene-L-arabinitol (C2):
At 0-10°C, 44.68 g (116.78 mmol) of lithium aluminium hydride are metered into a solution of 50 g (179.66 mmol) of C1 in 450 ml of THF, and the mixture is stirred until the reaction has ended. At 20°C, water and aqueous sodium hydroxide solution are then added, and the precipitated solid is filtered off and washed product-free using THF. The solution of the crude product is concentrated and freed completely from the solvent. This gives 53.26 g of C2 (105%) as a crude product which is used in this form for the subsequent step C3.
[0067] 1H-NMR (400 MHz, DMSO): 7.39-7.24 (m, 5H, H-7 to H-9), 4.81 (t, 1 H, 5.46 Hz, 1 -OH), 4.65 (d, 1 H, 5.84 Hz, 4-OH), 4.5 (s, 2H, 2xH-6), 4.15-4.00 (m, 2H, H-2 and H-3), 3.76 (qd, 1 H, 6Hz, 2.5 Hz, H-4), 3.7-3.55 (m, 2H, 2xH-1), 3.49-3.35 (m, 2H, 2x H-5), 1.38 (s, 3H, 10-CH3), 1.25 (s, 3H, 10-CH3).
[0068] 13C-NMR (75 MHz, CDCI3): 138.0, 128.8, 128.2, 128.1 (Ar), 108.9 (0-C-O), 77.7 (CH2), 76.9 (CH2), 73.8 (CH), 71.9 (CH), 68.9 (CH2), 61.0 (CH), 28.1 (CH3), 25.6 (CH3).
[0069] 1 -0-Benzyl-3,4-0-isopropylidene-2,5-di-0-methanesulphonyl-L-arabinitol (C3): At 20°C, 54.54 g (538.97 mmol) of triethylamine are added to a solution of 53.26 g (179.66 mmol assuming a yield of 100% in step C2) of C2 (crude product) in 450 ml of THF, and 39.39 g (431.17 mmol) of methanesulphonyl chloride are metered in at 0-10°C. The mixture is then stirred until the reaction has ended, water is added and the phases are separated. The aqueous phase is extracted with MTBE, and the combined organic phases are washed with sat. sodium chloride solution and dilute sodium bicarbonate solution. The solution of the crude product is concentrated and freed completely from the solvents. This gives 86.66 g of C3 (110%) as a crude product which is used in this form for the subsequent step C4.
[0070] H-NMR (400 MHz, CDCI3): 7.40-7.30 (m, 5H), 4.90 (dt, 1 H, 11.5 Hz, 6.6 Hz), 4.56 (dd, 2H, 11.8 Hz), 4.42-4.39 (m, 2H), 4.38-4.35 (m, 2H), 3.83 (dd, 1 H, 10.61 Hz, 6.06 Hz), 3.70 (dd, 1 H, 10.61 Hz, 5.05 Hz), 3.10 (s, 3H), 3.02 (s, 3H), 1.50 (s, 3H), 1.37 (s, 3H).
[0071] 13C-NMR (75 MHz, CDCI3): 136.8, 128.6, 128.2, 128.0 (Ar), 109.7 (0-C-O), 77.8. 75.6, 74.5, 73.7 (CH2), 69.6 (CH2), 67.7 (CH2), 39.0, 37.5, 27.2, 25.4.
[0072] 1 ,4-Anhydro-5-0-benzyl-2,3-0-isopropylidene-4-thio-D-ribitol (C4):
50.99 g (215.59 mmol) of sodium sulphide (33% pure) are added to a solution of 86.66 g (179.66 mmol assuming a yield of 100% in step C3) of C3 (crude product) in 550 ml of N-methyl-2-pyrrolidone, and the mixture is heated to an internal temperature of 80°C and stirred at this temperature until the reaction has ended. At an internal temperature of 20°C, water and MTBE are then added, the phases are separated and the aqueous phase is extracted with MTBE. The combined organic phases are finally washed with water. The solution of the crude product is concentrated and freed completely from the solvents. This gives 56.41 g of C4 (1 12%) as a crude product which is used in this form for the subsequent step C5.
[0073] 1H-NMR (400 MHz, DMSO): 7.40-7.25 (m, 5H, H-7 to H-9), 4.89 (t, 1 H, 4.7 Hz, H-2), 4.73 (d, 1 H, 5.65 Hz, H-3), 4.50 (s, 2H, 2xH-6), 3.55-3.42 (m, 2H, 2xH-5), 3.37 (t, 1 H, 6.2 Hz, H-4), 3.10 (dd, 1 H, 12.6 Hz, 4.7 Hz, H-1), 2.76 (d, 1 H, 12.6 Hz, H-1 ').
[0074] 13C-NMR (75 MHz, CDCI3): 137.9, 128.4, 127.9, 127.5 (Ar), 110.9 (0-C-O), 86.3 (CH), 83.8 (CH), 73.2 (CH2), 72.2 (CH2), 53.3 (CH), 38.3 (CH2), 27.2 (CH3), 25.3 (CH3).
[0075] 1 ,4-Anhydro-5-0-benzyl-4-thio-D-ribitol (C5):
A solution of 50 ml of water and 9.22 g (0.094 mmol) of sulphuric acid is added to the solution of 56.41 g (179.66 mmol assuming a yield of 100% in step C4) of C4 (crude product) in 450 ml of THF, and the mixture is heated to 70°C and stirred at this temperature for a plurality of hours. To achieve complete conversion, a few ml are distilled off at 70°C. MTBE is then added at 20°C, the phases are separated and the aqueous phase is extracted with MTBE. The combined organic phases are neutralized with saturated potassium carbonate solution. The solid is filtered off and washed product-free using MTBE. The solution of the crude product is redistilled to isopropyl acetate, and the product is crystallized by addition of heptane. This gives 33.67 g (78% over 4 steps starting with C1 ) of C5.
[0076] 1H-NMR (400 MHz, CDCI3): 7.39-7.29 (m, 5H), 4.56 (s, 2H), 4.37 (dt, 1 H, 7.33 Hz, 3.54 Hz), 4.04 (dt, 1 H, 7.07 Hz, 6.82 Hz), 3.70 (dd, 1 H, 9.09 Hz, 5.31 Hz), 3.62 (t, 1 H, 9.09 Hz), 3.56-3.51 (m, 1 H), 3.1 1 (d, 1 H, 3.54 Hz), 3.05 (dd, 1 H, 11.62 Hz, 4.55 Hz), 2.85 (dd, 1 H, 11.62 Hz, 3.03 Hz), 2.65 (d, 1 H, 3.54 Hz).
[0077] 3C-NMR (75 MHz, CDCI3): 137.4, 128.6, 128.0, 127.8 (Ar), 80.4, 74.8, 73.6 (CH2), 73.0 (CH2), 47.0, 33.6 (CH2).
Melting point: 78-82°C
[0078] 1 ,4-Anhydro-5-0-benzyl-2,3-0-sulphonyl-4-thio-D-ribitol (C6):
At 0°C, a solution of 50 g (208.06 mmol) of C5 in 75 ml of THF is added to a suspension of 2.5 g of sodium hydride (in mineral oil) in 100 ml of THF, and the mixture is stirred at 0°C for 1 -2 hours. At 0°C, a solution of 45.36 g of sulphonyldiimidazole in 450 ml of THF is then metered in, and the mixture is stirred at 20°C until the reaction is ended. In this form, the crude product is used directly for the subsequent step C7. [0079] 1H-NMR (400 MHz, CDCI3): 7.40-7.26 (m, 5H), 5.41 (dt, 1 H, 6.06 Hz, 3.28 Hz), 5.33 (dd, 1 H, 6.32 Hz, 2.78 Hz), 4.54 (d, 2H, 2.53 Hz), 3.81 (dd, 1 H, 9.85 Hz, 4.29 Hz), 3.72 (m, 1 H), 3.64 (dd, 1 H, 9.85 Hz, 4.80 Hz), 3.47 (dd, 1 H, 13.39 Hz, 5.81 Hz), 3.16 (dd, 1 H, 13.39 Hz, 3.28 Hz).
[0080] 13C-NMR (75 MHz, CDCI3): 137.0, 128.6, 128.2, 127.7 (Ar), 87.9, 86.1 , 73.7 (CH2), 71.2 (CH2), 51.6, 36.8 (CH2).
[0081] 1 ,4-Anhydro-5-0-benzyl-2-deoxy-2-fluoro-4-thio-D-arabinitol (C7):
At 20°C, a solution of 131.3 g of tetrabutylammonium fluoride trihydrate in 150 ml of THF is metered into the solution of the crude product from the preparation of compound C6. The mixture is stirred at 30°C until the reaction is ended.
The reaction mixture is then adjusted to pH 1 using sulphuric acid (33% strength) and stirred at 50°C until the reaction is ended. At 20°C, the pH is then adjusted to 7-10 using aqueous potassium hydroxide solution, and the precipitate formed is filtered off. The phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are concentrated and the crude product is, after complete removal of the solvent, purified by chromatography. This gives 22.68 g of C7 (45%).
[0082] 1H-NMR (400 MHz, CDCI3): 7.4-7.27 (m, 5H, H-7 to H-9), 5.04 (qd, 1 H, 51.7 Hz, 5.44 Hz, H-2), 4.55 (s, 2H, 2xH-6), 4.37 (td, 1 H, 11.7 Hz, 4.9 Hz, H-3), 3.68-3.55 (m, 2H, 2xH-5), 3.45-3.38 (m, 1 H, H-4), 3.2-2.99 (m, 2H, 2xH-1).
[0083] 13C-NMR (100 MHz, CDCI3): 137.65, 128.52, 127.91 , 127.77 (Ar), 97.27 (C-2), 79.10 (C-3), 73.46 (C-6), 72.69 (C-5), 48.58 (C-4), 31.72 (C-1).
19F-NMR (376 MHz, CDCI3): -183.14 (m, 2-F).
Melting point: 83-85°C
[0084] 1 ,4-Anhydro-2-deoxy-2-fluoro-4-thio-D-arabinitol (C8):
At a temperature of < -65°C, a solution, pre-cooled to -10°C, of 50 g (206.35 mmol) of C7 in 350 ml of dichloromethane is added to 546.82 g (412.69 mmol) of boron trichloride (1 mol/l in dichloromethane). After 30 minutes at < -65°C, the reaction is checked for complete conversion. A mixture of 150 ml of methanol and 116 ml of pyridine is then added at < -65°C to the reaction mixture, and the mixture is heated to 20°C after 15 minutes. The solvents are removed completely by distillation under reduced pressure. Dichloromethane is then added to the residue, and the solvent is removed completely. This gives 133 g of C8 (423%) as a crude product (contains residual amounts of pyridine and pyridinium hydrochloride) which is used in this form for the subsequent step C9.
[0085] 1H-NMR (400 MHz, DMSO): 5.49 (d, 1 H, 4.77 Hz, 3-OH), 4.98 (qd, 1 H, 51.55 Hz, 3.76 Hz, H-2), 4.94 (t, 1 H, 5.2 Hz, 5-OH), 4.17 (ddd, 1 H, 15.18 Hz, 4.14 Hz, 3.76 Hz H-3), 3.61-3.53 (m, 1 H, H-5), 3.37-3.30 (m, 1 H, H-5'), 3.19-3.02 (m, 2H, H-4 and H-1), 2.93 (ddd, 1 H, 18.22 Hz, 12.1 Hz, 3.76 Hz, H-1 ').
[0086] 13C-NMR (75 MHz, CDCI3): 97.1 (d, 185 Hz, C-2), 77.5 (d, 24 Hz, C-3), 63.3 (d, 3 Hz, C-5), 50.9 (d, 4 Hz, C-4), 31.1 (d, 22 Hz, C-1).
[0087] 1 ,4-Anhydro-2-deoxy-2-fluoro-3,5-di-0-benzoyl-4-thio-D-arabinitol (C9):
133 g (206.35 mmol assuming a yield of 100% in step C8) of C8 (crude product) are dissolved in 400 ml of dichloromethane, and 97.92 g (1237.9 mmol) of pyridine are added. 87.01 g (618.97 mmol) of benzoyl chloride are then added dropwise at 10°C, and the mixture is stirred at 20°C until the reaction has ended. Methanol is then added, and the mixture is stirred for 1 hour. Finally, water is added and the phases are separated. The solution of the crude product is concentrated and freed completely from the solvent. This gives 114.53 g of C9 (154%) as a crude product which is used in this form for the subsequent step C10.
[0088] 1H-NMR (400 MHz, CDCI3): 8.20-8.00 (m, 4H), 7.65-6.90 (m, 6H), 5.85 (dt, 1 H, 9.98 Hz, 2.64 Hz), 5.40 (ddd, 1 H, 48.79 Hz, 7.16 Hz, 3.01 Hz), 4.54 (s, 1 H), 4.51 (s, 1 H), 3.95-3.82 (m, 1 H), 3.45-3.35 (m, 1 H), 3.35-3.28 (m, 1 H).
[0089] 13C-NMR (75 MHz, CDCI3): 165.0 (C=0), 133.6, 133.1 , 129.8, 129.7, 128.5, 128.4, 96.5 (d, 184 Hz, C-2), 79.0 (d, 29 Hz, C-3), 65.2 (d, 4 Hz, C-5), 48.5 (C-4), 34.9 (d, 23 Hz, C-1 ).
[0090] 1 ,4-Anhydro-2-deoxy-2-fluoro-3,5-di-0-benzoyl-4-sulphinyl-D-arabinitol (C10): 114.53 g (206.35 mmol assuming a yield of 100% in step C9) of C9 (crude product) are dissolved in 400 ml of acetone, and 60 ml of water are added. At 20°C, 69.77 g
(113.49 mmol) of OXONE are then added a little at a time. The reaction is checked for complete conversion, and a dilute solution of sodium sulphite is then added. The reaction mixture is neutralized using saturated sodium bicarbonate solution, and the acetone is then removed completely by distillation under reduced pressure.
Dichloromethane is added to the suspension, the solid is filtered off and the filtercake is washed product-free with dichloromethane. The solution of the crude product is redistilled to MTBE and isolated in this solvent. This gives 56.4 g (72.6% over three steps with C7) of C10.
[0091] 1H-NMR (400 MHz, CDCI3): 8.05 (m, 4H), 7.60 (m, 2H), 7.45 (m, 4H), 5.83 (m, 1 H), 5.74 (m, 1 H), 4.89 (ddd, 1 H, 12.1 Hz, 5.1 Hz, 0.9 Hz), 4.75 (ddd, 1 H, 12.4 Hz, 7.6 Hz, 0.9 Hz), 3.65 (m, 1 H), 3.75 (m, 1 H), 3.45 (m, 1 H).
[0092] 13C-NMR (75 MHz, CDCI3): 165.7, 165.2 (C=0), 134.0, 133.5, 130.0, 129.7, 128.6, 128.5 (Ar), 95.4 (d, 185 Hz, C-2), 77.2 (d, 33 Hz, C-3), 71.6 (C-4), 61.1 (d, 2 Hz, C-5), 55.8 (d, 19 Hz, C-1).
[0093] 1 -0-Acetyl-2-deoxy-2-fluoro-3,5-di-0-benzoyl-4-thio-P-D-arabinofuranose (ΙΙβ): 80 ml of acetic anhydride and 361 mg (2.66 mmol) of potassium bisulphate are added to 10 g (26.57 mmol) of C10, and the mixture is stirred at 80°C until the reaction is ended. The reaction mixture is then codistilled initially repeatedly with toluene and then with ethanol. Finally, the product is crystallized from ethanol. This gives 8.9 g (80%) of the compound ΙΙβ.
[0094] 1H-NMR (400 MHz, CDCI3): 8.10-7.90 (m, 4H, Ar), 7.63-7.29 (m, 6H, Ar), 6.18 (d, 1 H, 4.4 Hz), 6.12-6.02 (m, 1 H), 5.45 (dd, 1 H, 9.04 Hz, 4.52 Hz), 5.28 (dd, 1 H, 8.85 Hz, 4.52 Hz), 4.68 (dd, 1 H, 11.49 Hz, 6.22 Hz), 4.49 (dd, 1 H, 11.49 Hz, 6.41 Hz), 3.74 (dd, 1 H, 13.56 Hz, 6.40 Hz), 2.12 (s, 3H).
[0095] 13C-NMR (75 MHz, CDCI3): 169.6 (COCH3), 165.8, 165.4 (COPh), 133.6, 133.1 (Ar) 129.8, 129.7, 128.5, 128.2 (Ar), 92.5 (d, 207 Hz, C-2), 75.7 (d, 23 Hz, C-3), 74.0 (d, 17 Hz, C-1), 66.1 (C-5), 42.4 (d, 7 Hz, C-4), 21.0 (CH3).
Melting point: 130°C
Industrial Applicability
[0096] The process of the present invention provides an industrially advatageous and excellent preparation of the compounds of the formula I.

Claims

Claims
[Claims 1] A process for preparing a compound of formula I
Figure imgf000028_0001
I wherein
R1 represents -C(0)-C C6-alkyl or -C(0)-aryl; and
R2 represents Ci-C6-alkyl, Ci-C4-perfluoroalkyl or aryl,
which comprises the following steps:
(1) reduction of a lyxonolactone of formula IV
Figure imgf000028_0002
IV wherein
R6 represents d-C6-alkyl or arylmethylene; and
R7 and R8 independently represent hydrogen, CrC6-alkyl, C C4-perfluoroalkyl or in the presence of 0.5-10 molar equivalents of hydride donors of the formula A(AIH4) or A(BH4), wherein A is an alkali metal, to give the diol of the formula V: OH
60
Figure imgf000029_0001
(2) reaction of the diol of formula V with at least 2 molar equivalents of sulphonyl chloride R9-SO2CI or sulphonic anhydride R9-SO2-O-SO2-R9, wherein R9 represents CrC6-alkyl, Ci-C4-perfluoroalkyl or aryl, in the presence of at least 2 molar equivalents of a tertiary amine or a pyridine, to give the compound of formula VI:
Figure imgf000029_0002
VI
(3) reaction of the bissulphonate of formula VI with at least 1 molar equivalent of sodium sulphide (Na2S) in a polar aprotic solvent, at a temperature of more than 50°C, to give the thiofuranose of formula VII:
Figure imgf000029_0003
VII
(4) conversion of the thiofuranose of formula VII in a solvent mixture of water and an organic solvent selected from the group of the ethers, alcohols, and aromatic hydrocarbons, with 0.01 -5 molar equivalents of an acid selected from the group of the mineral acids, alkanesulphonic acids, arylsulphonic acids, perfluorosulphonic acids and perfluoroalkanecarboxylic acids, into the diol of formula VIII:
Figure imgf000030_0001
vm
(5) reaction of the diol of formula VIII in the presence of at least 0.2 molar equivalents of a base of the formula AH, A2C03 or A(OtBu), wherein A represents an alkali metal; with 1 -2 molar equivalents of a diol-activating reagent of the formula X S02-X2, wherein and X2 independently represent CI or imidazoyl, to give the cyclic sulphate ester of formula IX:
Figure imgf000030_0002
(6) the cyclic sulphate ester of formula IX is initially reacted with 1 -3 molar equivalents of an ammonium fluoride of the formula N(Rn)4F, wherein R represents CrC6-alkyl, at a temperature between 0°C and 30°C, and the reaction mixture obtained in this manner is reacted with an acid selected from the group of the mineral acids, alkylsulphonic acids, arylsulphonic acids, perfluorosulphonic acids and
perfluoroalkanecarboxylic acids to give the ether of formula X:
Figure imgf000031_0001
X
(7) the ether of formula X is
in partial step a) reacted in the presence of at least 1 molar equivalent of a boron halide BY3, wherein Y represents F, CI or Br, at a temperature between 0°C and -80°C;
in partial step b), the reaction mixture obtained in partial step a) is reacted with a mixture of an alcohol component selected from the group consisting of a Ci-C6-alkanol, an aryl alkanol and phenols; and a base selected from the group of the aliphatic tertiary amines and pyridines; to give the diol of formula XI:
Figure imgf000031_0002
(8) the diol of formula XI is in the presence of at least 2 molar equivalents of a base selected from the group of aliphatic tertiary amines and pyridines, reacted with at least 2 molar equivalents of an acid chloride R1-C1 or an acid anhydride R1-O-R1, wherein Ri represents -C(0)-Ci-C6-alkyl or -C(0)-aryl; to give the compound of formula XII:
Figure imgf000031_0003
XII
(9) the sulphide of formula XII is oxidized in a solvent mixture of water and a ketone of the formula R9-C(0)-R9', wherein R9 and R9' independently represents C1 -C6- alkyl, CrC4-perfluoroalkyl or aryl, with 0.5-1 molar equivalent of an alkali metal persulphate of the formula AHS05, wherein A+ represents an alkali metal, at a temperature between 0°C and 50°C to give the sulphoxide of formula XIII:
Figure imgf000032_0001
xm
(10) the sulphoxide of formula XIII is reacted with at least 1 molar equivalent of an acid anhydride R2-C(0)-0-C(0)-R2, wherein R2 represents CrC6-alkyl, C1-C4- perfluoroalkyl or aryl; in the presence of 0.01 -2 molar equivalents of a protic acid selected from mineral acids, alkanesulphonic acids, arylsulphonic acids,
perfluorosulphonic acids and perfluoroalkanecarboxylic acids
or
in the presence of 0.01 -2 molar equivalents of a Lewis acid or arylmethylene; at a temperature between 30°C and 100°C.
[Claims 2] The process according to Claim 1 for preparing compounds of the formula I wherein
Ri represents benzoyl, and
R2 represents methyl.
[Claims 3] The process according to Claim 2 for preparing the compound of the formula ΙΙβ,
Figure imgf000033_0001
wherein
R7) Re and R9 represent methyl, and
R6 represents benzyl.
[Claims 4] The process according to any of the preceding claims, wherein in step
(1 ) 0.5-1.5 molar equivalents of lithium aluminium hydride (LiAIH4) are used.
[Claims 5] The process according to any of the preceding claims, wherein the step
(1 ) and/or the step (2) are carried out at a temperature between 0°C and 30°C.
[Claims 6] The process according to any of the preceding claims, wherein in step
(2) 2-5 molar equivalents of methanesulphonyl chloride and 2-5 molar equivalents of triethylamine are used.
[Claims 7] The process according to any of the preceding claims, wherein the reaction in step (3) is carried out at a temperature between 50°C and 100°C in
N-methylpyrrolidone.
[Claims 8] The process according to any of the preceding claims, wherein the reaction in step (4) is carried out in a mixture of tetrahydrofuran (THF) and water with 0.01 -5 molar equivalents of H2S0 at a temperature between 20°C and 100°C.
[Claims 9] The process according to any of the preceding claims, wherein in step
(4) the isolation of the diol VIII is carried out by crystallization from a solvent mixture of heptane and isopropyl acetate or ethyl acetate.
[Claims 10] The process according to any of the preceding claims, wherein in step
(5) 0.2-3 molar equivalents of sodium hydride and 1 -2 molar equivalents of sulphonyldiimidazole are used at a temperature between -5°C and 20°C.
[Claims 1 1] The process according to any of the preceding claims, wherein in step
(6) 1 -3 molar equivalents of tetrabutylammonium fluoride are used.
[Claims 12] The process according to any of the preceding claims, wherein in step
(6) the reaction mixture obtained in the first partial step is reacted at a temperature between 20°C and 70°C with sulphuric acid (H2S04).
[Claims 13] The process according to any of the preceding claims, wherein in partial step a) of step (7) 1 -4 molar equivalents of boron trichloride are used.
[Claims 14] The process according to any of the preceding claims, wherein in partial step b) of step (7) the reaction mixture of methanol and pyridine obtained in partial step a) is reacted.
[Claims 15] The process according to any of the preceding claims, wherein the partial steps of step (7) are carried out at temperatures between 0°C and -80°C.
[Claims 16] The process according to any of the preceding claims, wherein step (8) is carried out in the presence of 2-10 molar equivalents of pyridine using 2-5 molar equivalents of benzoyl chloride.
[Claims 17] The process according to any of the preceding claims, wherein step (9) is carried out in a solvent mixture of water and acetone using 0.5-1 molar equivalent of OXONE.
[Claims 18] The process according to any of the preceding claims, wherein in step
(9) the sulphoxide XIII is isolated by crystallization from methyl tert-butyl ether.
[Claims 19] The process according to any of the preceding claims, wherein step
(10) is carried out in the presence of 0.01 -2 molar equivalents of potassium bisulphate using at least 5 molar equivalents of acetic anhydride.
[Claims 20] The process according to any of the preceding claims, wherein in step (10) the product I is isolated by crystallization from ethanol.
[Claims 21] A process for preparing a compound of the formula I:
Figure imgf000035_0001
I wherein
Ri represents -C(0)-CrC6-alkyl or -C(0)-aryl; and
R2 represents CrC6-alkyl, Ci-C4-perfluoroalkyl or aryl,
which comprises reacting the sulphoxide of formula XIII:
Figure imgf000035_0002
XIII wherein represents benzoyl, at a temperature between 30°C and 100°C with at least 1 molar equivalent of an acid anhydride R2-C(0)-0-C(0)-R2, wherein R2 represents CrC6-alkyl, CrC4-perfluoroalkyl or aryl; in the presence of 0.01 -2 molar equivalents of a protic acid selected from the group of mineral acids, alkanesulphonic acids,
arylsulphonic acids, perfluorosulphonic acids and perfluoroalkanecarboxylic acids or
in the presence of 0.01 -2 molar equivalents of a Lewis acid, wherein R13 represents C C6-alkyl or arylmethylene.
[Claims 22] The process according to Claim 21 , wherein the reaction is carried out in the presence of 0.01 -2 molar equivalents of potassium bisulphate using at least 5 molar equivalents of acetic anhydride.
[Claims 23] The process according to Claim 21 , wherein the product ΙΙβ is isolated by crystallization from ethanol.
[Claims 24] The process for preparing a compound of formula X
Figure imgf000036_0001
x wherein R6 represents d-C6-alkyl, arylmethylene,
which comprises the following steps:
(a) the cyclic sulphate ester of formula IX
IX is initially reacted with 1 -3 molar equivalents of an ammonium fluoride of the formula N(Ri1)4F, wherein R represents d-Ce-alkyl, at a temperature between 0°C and 30°C, and
(b) the reaction mixture obtained in this manner is reacted with an acid selected from the group of mineral acids, alkylsulphonic acids, arylsulphonic acids,
perfluorosulphonic acids and perfluoroalkanecarboxylic acids.
[Claims 25] The process according to Claim 24, wherein 1 -3 molar equivalents of tetrabutylammonium fluoride are used.
[Claims 26] The process according to Claim 24, wherein the reaction mixture obtained in the first partial step is reacted at a temperature between 20°C and 70°C with sulphuric acid (H2S04).
[Claims 27] An intermediate produced by the process according to any of the preceding claims, which is selected from
1-0-benzyl-3,4-0-isopropylidene-L-arabinitol;
1-0-benzyl-3,4-0-isopropylidene-2,5-di-0-methanesulphonyl-L-arabinitol;
1 ,4-anhydro-5-0-benzyl-2,3-0-isopropylidene-4-thio-D-ribitol;
1 ,4-anhydro-5-0-benzyl-2,3-0-sulphonyl-4-thio-D-ribitol; and
1 ,4-anhydro-5-0-benzyl-2-deoxy-2-fluoro-4-thio-D-arabinitol.
PCT/JP2010/072182 2009-12-18 2010-12-03 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES WO2011074484A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP10801279.0A EP2513081B1 (en) 2009-12-18 2010-12-03 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES
MX2012006872A MX2012006872A (en) 2009-12-18 2010-12-03 Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thi o-î²-d-arabinofuranoses.
SG2012044368A SG181745A1 (en) 2009-12-18 2010-12-03 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES
AU2010331367A AU2010331367B2 (en) 2009-12-18 2010-12-03 Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses
JP2012527135A JP5616968B2 (en) 2009-12-18 2010-12-03 Method for producing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-β-D-arabinofuranoses
BR112012014490-1A BR112012014490B1 (en) 2009-12-18 2010-12-03 PROCESSES FOR THE PREPARATION OF 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-?-D-ARABINOFUURANOSES AND INTERMEDIATE COMPOUNDS THEREOF
NZ601222A NZ601222A (en) 2009-12-18 2010-12-03 Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-?-d-arabinofuranoses
CA2784399A CA2784399C (en) 2009-12-18 2010-12-03 Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-.beta.-d-arabinofuranoses
RU2012130422/04A RU2559364C2 (en) 2009-12-18 2010-12-03 METHOD OF OBTAINING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
CN201080057198.7A CN102656154B (en) 2009-12-18 2010-12-03 Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses
KR1020127018741A KR101814549B1 (en) 2009-12-18 2010-12-03 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
IL220357A IL220357A (en) 2009-12-18 2012-06-13 Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-ß-d-arabinofuranoses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09075563.8 2009-12-18
EP09075563 2009-12-18
EP10163406.1 2010-05-20
EP10163406A EP2388257A1 (en) 2010-05-20 2010-05-20 Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-ß-D-arabinofuranoses

Publications (1)

Publication Number Publication Date
WO2011074484A1 true WO2011074484A1 (en) 2011-06-23

Family

ID=43587023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/072182 WO2011074484A1 (en) 2009-12-18 2010-12-03 PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES

Country Status (16)

Country Link
US (2) US8329925B2 (en)
EP (2) EP2799432B1 (en)
JP (1) JP5616968B2 (en)
KR (1) KR101814549B1 (en)
CN (1) CN102656154B (en)
AU (1) AU2010331367B2 (en)
BR (1) BR112012014490B1 (en)
CA (1) CA2784399C (en)
IL (1) IL220357A (en)
MX (1) MX2012006872A (en)
MY (1) MY156954A (en)
NZ (1) NZ601222A (en)
RU (1) RU2559364C2 (en)
SG (1) SG181745A1 (en)
TW (1) TWI476204B (en)
WO (1) WO2011074484A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182028A1 (en) * 2012-06-04 2013-12-12 浙江九洲药物科技有限公司 Synthesis process for a five-membered ring sulphate compound
WO2014027658A1 (en) 2012-08-13 2014-02-20 富士フイルム株式会社 INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
WO2015125782A1 (en) * 2014-02-18 2015-08-27 富士フイルム株式会社 Method for producing thiolane-skeleton glycoconjugate, and thiolane-skeleton glycoconjugate
US9815812B2 (en) 2014-02-19 2017-11-14 Fujifilm Corporation Thiopyranose compound and method for producing same
US9884882B2 (en) 2014-02-18 2018-02-06 Fujifilm Corporation Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
US9896471B2 (en) 2012-03-28 2018-02-20 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine
US10059734B2 (en) 2014-10-31 2018-08-28 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
KR20180104115A (en) 2016-02-29 2018-09-19 후지필름 가부시키가이샤 Liquid pharmaceutical preparation
KR20190034310A (en) 2016-08-31 2019-04-01 후지필름 가부시키가이샤 Antitumor agent, antitumor effect enhancer and anti-tumor kit
WO2019176984A1 (en) 2018-03-13 2019-09-19 富士フイルム株式会社 Antitumor agent, antitumor effect potentiator and antitumor kit
US11141421B2 (en) 2018-01-29 2021-10-12 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO2023008511A1 (en) 2021-07-29 2023-02-02 富士フイルム株式会社 Pharmaceutical composition and anti-tumor agent for tumors that have at least either impaired bap1 or pbrm1 function

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012386B (en) * 2012-12-26 2015-04-01 浙江普洛得邦制药有限公司 Preparation method of five-membered cyclic sulphate
JP6245527B2 (en) * 2014-03-24 2017-12-13 富士フイルム株式会社 Method for producing compound having thiolane ring or thiane ring skeleton
CN106810541A (en) * 2016-12-30 2017-06-09 苏州诚和医药化学有限公司 A kind of method that one-step method prepares Suo Feibuwei intermediates
JP2017214422A (en) * 2017-09-01 2017-12-07 富士フイルム株式会社 Compounds useful for manufacturing salacinol, method for manufacturing the same, method for manufacturing salacinol, methods for protecting and deprotecting diol group, and protective agent for diol group

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803272A (en) * 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
WO1997003993A1 (en) 1995-07-20 1997-02-06 Mallinckrodt Medical, Inc. Process for producing tungsten clusters
WO1997038001A1 (en) 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
US6448415B1 (en) 2000-07-22 2002-09-10 Hanchem Co., Ltd. Chirality conversion method in lactone sugar compounds
WO2007068113A1 (en) 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808272A (en) * 1986-06-20 1989-02-28 Spalding & Evenflo Companies, Inc. Method of constructing a mold for making game balls
EP0839813A1 (en) 1996-04-09 1998-05-06 Yamasa Corporation 9-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)purine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803272A (en) * 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
WO1997003993A1 (en) 1995-07-20 1997-02-06 Mallinckrodt Medical, Inc. Process for producing tungsten clusters
WO1997038001A1 (en) 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
US6147058A (en) * 1996-04-09 2000-11-14 Yamasa Corporation 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
US6448415B1 (en) 2000-07-22 2002-09-10 Hanchem Co., Ltd. Chirality conversion method in lactone sugar compounds
WO2007068113A1 (en) 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
D.A. ZAJCHOWSKI ET AL., INT. J. CANCER, vol. 114, 2005, pages 1002 - 1009
D.C. BAKER ET AL., CARBOHYDR. RES., vol. 24, 1972, pages 192 - 197
J.K WATTS ET AL., J. ORG. CHEM., vol. 71, 2006, pages 921 - 925
J.K. WATTS ET AL., J. ORG. CHEM., vol. 71, 2006, pages 921 - 925
KOMINE TAKASHI ET AL: "Synthesis and structure-activity relationship studies of highly potent novel oxazolidinone antibacterials.", JOURNAL OF MEDICINAL CHEMISTRY 23 OCT 2008 LNKD- PUBMED:18826297, vol. 51, no. 20, 23 October 2008 (2008-10-23), pages 6558 - 6562, XP002606719, ISSN: 1520-4804 *
LAK SHIN JEONG ET AL: "N6-Substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US LNKD- DOI:10.1021/JM034098E, vol. 46, no. 18, 23 August 2003 (2003-08-23), pages 3775 - 3777, XP002540593, ISSN: 0022-2623 *
S. MIURA ET AL., CANCER LETT., vol. 129, 1998, pages 103 - 110
S. MIURA ET AL., CANCER LETT., vol. 144, no. 17, 1999, pages 7 - 182
VANHESSCHE K ET AL: "L-RIBULOSE: A NOVEL CHIRAL POOL COMPOUND", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/0040-4039(90)80222-8, vol. 31, no. 16, 1 January 1990 (1990-01-01), pages 2337 - 2340, XP000561142, ISSN: 0040-4039 *
VARELA O. ET AL: "First Synthesis of Aldopentono-1,4-thiolactones", JOURNAL OF ORGANIC CHEMISTRY, vol. 58, December 1993 (1993-12-01), pages 7860 - 7864, XP002606718, DOI: 10.1021/jo00079a034 *
WANG C -L J ET AL: "Synthesis of 2'(S), 3'(R), 5'-trihydroxypentyladenine", TETRAHEDRON LETTERS 1988 GB LNKD- DOI:10.1016/S0040-4039(00)86662-9, vol. 29, no. 10, 1988, pages 1107 - 1110, XP002606717, ISSN: 0040-4039 *
WATTS J.K. ET AL: "Synthesis and conformational analysis of 2'-fluoro-5-methyl-4'-thioarabinouridine (4'S-FMAU)", JOURNAL OF ORGANIC CHEMISTRY, vol. 71, no. 3, 11 January 2006 (2006-01-11), pages 921 - 925, XP002606716, DOI: 10.1021/jo051844+ *
Y. YOSHIMURA ET AL., BIOORG. MED. CHEM., vol. 8, 2000, pages 1545 - 1558
Y. YOSHIMURA ET AL., J. ORG. CHEM., vol. 62, 1997, pages 3140 - 3152
Y. YOSHIMURA ET AL., J. ORG. CHEM., vol. 64, 1999, pages 7912 - 7920
Y. YOSHIMURA ET AL., NUCLEIC ACIDS SYMPOSIUM SERIES, vol. 39, 1998, pages 11 - 12
Y. YOSHIMURA ET AL., NUCLEOTIDES NUCLEOTIDES, vol. 18, 1999, pages 815 - 820
Y. YOSHIMURA ET AL., TETRAHEDRON LETT., vol. 40, 1999, pages 1937 - 1940
YOSHIMURA Y ET AL: "A novel synthesis of 2'-modified 2'-deoxy-4'-thiocytidines from D-glucose", JOURNAL OF ORGANIC CHEMISTRY 1997 US LNKD- DOI:10.1021/JO9700540, vol. 62, no. 10, 1997, pages 3140 - 3152, XP002606720, ISSN: 0022-3263 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9896471B2 (en) 2012-03-28 2018-02-20 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine
WO2013182028A1 (en) * 2012-06-04 2013-12-12 浙江九洲药物科技有限公司 Synthesis process for a five-membered ring sulphate compound
CN103450148A (en) * 2012-06-04 2013-12-18 浙江九洲药业股份有限公司 Synthetic method of five-membered cyclic derivative sulfate compounds
CN103450148B (en) * 2012-06-04 2018-06-12 浙江九洲药业股份有限公司 A kind of synthetic method of five-membered ring sulfate compound
US9475835B2 (en) 2012-08-13 2016-10-25 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl) cytosine, synthetic intermediate of thionucleoside, and method for producing the same
WO2014027658A1 (en) 2012-08-13 2014-02-20 富士フイルム株式会社 INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES
JPWO2014027658A1 (en) * 2012-08-13 2016-07-28 富士フイルム株式会社 Synthetic intermediates of 1- (2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl) cytosine, synthetic intermediates of thionucleosides, and methods for producing them
US10570112B2 (en) 2012-08-13 2020-02-25 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same
JP2016185979A (en) * 2012-08-13 2016-10-27 富士フイルム株式会社 SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THEM
KR20170001723A (en) 2012-08-13 2017-01-04 후지필름 가부시키가이샤 SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THE SAME
KR20170001722A (en) 2012-08-13 2017-01-04 후지필름 가부시키가이샤 SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THE SAME
EP3184112A1 (en) 2012-08-13 2017-06-28 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-ss-d-arabinofuranosyl)cytosine
US10093645B2 (en) 2012-08-13 2018-10-09 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same
US9221865B2 (en) 2012-08-13 2015-12-29 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same
US9884882B2 (en) 2014-02-18 2018-02-06 Fujifilm Corporation Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
WO2015125782A1 (en) * 2014-02-18 2015-08-27 富士フイルム株式会社 Method for producing thiolane-skeleton glycoconjugate, and thiolane-skeleton glycoconjugate
JP2015172033A (en) * 2014-02-18 2015-10-01 富士フイルム株式会社 Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
US9815812B2 (en) 2014-02-19 2017-11-14 Fujifilm Corporation Thiopyranose compound and method for producing same
US10385089B2 (en) 2014-10-31 2019-08-20 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
US10059734B2 (en) 2014-10-31 2018-08-28 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
KR20180104115A (en) 2016-02-29 2018-09-19 후지필름 가부시키가이샤 Liquid pharmaceutical preparation
US11382927B2 (en) 2016-02-29 2022-07-12 Fujifilm Corporation Liquid medicinal preparation
KR20190034310A (en) 2016-08-31 2019-04-01 후지필름 가부시키가이샤 Antitumor agent, antitumor effect enhancer and anti-tumor kit
US11369625B2 (en) 2016-08-31 2022-06-28 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
US11141421B2 (en) 2018-01-29 2021-10-12 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO2019176984A1 (en) 2018-03-13 2019-09-19 富士フイルム株式会社 Antitumor agent, antitumor effect potentiator and antitumor kit
WO2023008511A1 (en) 2021-07-29 2023-02-02 富士フイルム株式会社 Pharmaceutical composition and anti-tumor agent for tumors that have at least either impaired bap1 or pbrm1 function
KR20240028451A (en) 2021-07-29 2024-03-05 후지필름 가부시키가이샤 Pharmaceutical composition and anti-tumor agent for tumors with decreased function of at least one of BAP1 and PBRM1

Also Published As

Publication number Publication date
TW201121987A (en) 2011-07-01
CN102656154A (en) 2012-09-05
AU2010331367A1 (en) 2012-08-02
JP2013514260A (en) 2013-04-25
EP2799432B1 (en) 2016-09-21
EP2799432A1 (en) 2014-11-05
US20110152542A1 (en) 2011-06-23
KR101814549B1 (en) 2018-01-04
CA2784399C (en) 2018-01-02
EP2513081B1 (en) 2015-07-08
BR112012014490B1 (en) 2021-07-13
KR20120096088A (en) 2012-08-29
IL220357A0 (en) 2012-08-30
US20130005991A1 (en) 2013-01-03
EP2513081A1 (en) 2012-10-24
MX2012006872A (en) 2012-09-12
AU2010331367A2 (en) 2013-01-24
RU2559364C2 (en) 2015-08-10
BR112012014490A2 (en) 2015-09-15
IL220357A (en) 2015-11-30
US8420831B2 (en) 2013-04-16
SG181745A1 (en) 2012-07-30
MY156954A (en) 2016-04-15
US8329925B2 (en) 2012-12-11
RU2012130422A (en) 2014-01-27
TWI476204B (en) 2015-03-11
JP5616968B2 (en) 2014-10-29
AU2010331367B2 (en) 2017-04-20
NZ601222A (en) 2013-09-27
CN102656154B (en) 2014-04-09
CA2784399A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
AU2010331367B2 (en) Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranoses
CA2167361C (en) 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
JP5544553B2 (en) Process for producing pyripyropene derivative and its intermediate
KR100312389B1 (en) Process for preparing alpha-anomer enriched ribofuranosyl derivative at low temperature
US6103707A (en) 9-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)purine derivatives
AU2007354030B2 (en) A novel and highly stereoselective process for preparing gemcitabine and intermediates thereof
Jackowski et al. Formation of septanoses from hexopyranosides via 5, 6-exo-glycals
EP2388257A1 (en) Process for preparing substituted 1-O-acyl-2-deoxy-2-fluoro-4-thio-ß-D-arabinofuranoses
CN112661802B (en) Synthetic method of 3&#39; -methoxyguanosine
US6388103B2 (en) Preparation method of arbutin intermediates
WO1991002741A1 (en) Sugar alcohol derivatives, a process for preparing 3-deoxy-2-octulosonic acid and 3-deoxy-2-heptulosonic acid compounds and derivatives
WO1997021719A1 (en) α, α-DIFLUORO-β-HYDROXY THIOL ESTERS AND THEIR SYNTHESIS
WO2013046180A1 (en) Method for making a precursor of l-fucose from d-glucose
WO2021043631A1 (en) Intermediates useful for preparing iduronic acid containing di- and polysaccharides
US20100056771A1 (en) Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor
CN116554237A (en) Preparation method and application of fluoro ribose intermediate
KR100834711B1 (en) A method of synthesizing n-acyl-5&#39;-deoxy-5-fluoroucytidine derivers

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080057198.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10801279

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012527135

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 220357

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2784399

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12012501205

Country of ref document: PH

Ref document number: MX/A/2012/006872

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201002860

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2010331367

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6251/CHENP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20127018741

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012130422

Country of ref document: RU

Ref document number: 2010801279

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010331367

Country of ref document: AU

Date of ref document: 20101203

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012014490

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012014490

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120614